The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Name: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
License: Public Domain

Zhejiang University

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

colorectalneoplasms ras

colorectal neoplasms, ras, braf, cetuximabβ, fruquintinib

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 226258
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.